EVTCY - EVTCY STOCK NEWS

Evotec SE has confirmed the integrity of its operations following a cyber attack detected on April 6, 2023. Immediate actions were taken to secure all IT systems, which were temporarily taken offline to prevent data breaches. A forensic examination is currently being conducted by external experts to assess the situation. Despite the incident, business continuity has been maintained across all global sites, ensuring that services remain available to partners, albeit with potential delays in communication. Evotec has informed relevant authorities and will continue to update stakeholders through its website. The company remains committed to protecting data integrity and is implementing solutions to improve communication efficiency.

Evotec SE experienced a cyber attack on its IT systems on April 6, 2023. In response, the company proactively shut down and disconnected its systems from the Internet to prevent potential data breaches and corruption. Currently, the systems are under examination, and the company is assessing the impact of the attack while ensuring the highest standards of data integrity are maintained. Evotec has not reported any confirmed data loss or breaches at this time.

Evotec SE has extended and expanded its strategic partnership with Bristol Myers Squibb (BMY) for an additional 8 years, aimed at developing therapies for neurodegenerative diseases. This collaboration builds on their productive history since 2016, addressing significant unmet medical needs. The deal includes a $50 million upfront payment, milestone payments, and tiered royalties on product sales, with a deal potential of $4 billion. This partnership aims to leverage Evotec's precision medicine platforms to enhance drug discovery and development for debilitating neurological conditions.

Evotec SE reported a 22% increase in group revenues for the fiscal year 2022, reaching €751.4 million, exceeding its targets. The adjusted Group EBITDA was €101.7 million. The company's base business surged by 30% to €725.3 million. Positive developments include an extended alliance with Bristol Myers Squibb and multiple new strategic partnerships in various therapeutic areas. For 2023, Evotec forecasts revenues between €820 - €840 million and an adjusted EBITDA of €115 - €130 million.

Evotec has secured a US$ 6.6 million grant from the Bill & Melinda Gates Foundation to enhance its tuberculosis (TB) drug discovery efforts. This funding, the second from the foundation, will support the development of new TB treatment regimens aimed at creating a universal, shorter, and safer alternative to current therapies. The initiative aligns with UN Sustainable Development Goal 3, which focuses on health and well-being. The current TB treatment regimens are lengthy and often complicated, highlighting the need for innovative solutions to combat drug-resistant TB, which remains a critical public health issue.

Evotec SE will announce its preliminary financial results for 2022 on March 28, 2023. A conference call will take place at 02:00 PM CEST to discuss these results, along with updates on company performance. Participants can join via phone or audio webcast, with detailed registration and access information provided. Evotec operates as a life science company focused on developing innovative therapeutics through a unique multimodality platform, collaborating with top pharmaceutical firms and over 800 biotech companies. The company aims to enhance its pipeline in key therapeutic areas including oncology and neurology.

Evotec SE announced progress in its partnership with Bristol Myers Squibb, specifically in the development of a molecular glue-based pipeline. This advancement has triggered performance-based payments totaling US$ 75 million to Evotec. The collaboration, established in 2018 and further expanded in May 2022, aims to develop novel molecular glue degraders targeting oncology and more. The company's innovative approach leverages advanced technologies to enhance drug discovery, potentially leading to significant therapeutic advancements. This partnership emphasizes Evotec's commitment to building a leading pipeline through systematic molecular glue development.

Evotec has secured a €150 million unsecured loan from the European Investment Bank (EIB) to enhance its R&D activities, make equity investments, and construct a new biologics manufacturing facility named J.POD in Toulouse, France. This follows a previous loan of €75 million granted in 2017. The funding aims to support innovative research in underserved therapeutic areas and is expected to create over 200 jobs in the region. The financing agreement reinforces Evotec's commitment to advancing precision medicine and expanding its global access to therapeutics.

Evotec SE has announced an extension and expansion of its collaboration with Related Sciences, focusing on advancing transformational new medicines through 2030. This partnership, initiated in early 2021, currently oversees over 15 drug discovery programs, leveraging Evotec's extensive expertise in integrated drug discovery and A.I./M.L. capabilities. The collaboration includes the discovery of covalent inhibitors, enhancing their multi-modality portfolio. Although the financial specifics of the agreement were not disclosed, Evotec is set to receive milestones, royalties, and an equity stake in RS assets developed under this partnership.